1
|
Fanetti G, Polesel J, Matrone F, Turturici I, Gobitti C, Alfieri S, Lupato V, La Torre F, Fratta E, Muraro E, Casarotto M, Guerrieri R, Giacomarra V, Steffan A, Vaccher E, Franchin G. PO-0965 Vitamin D, vitamin B12 and acute toxicity in head and neck cancer patients undergoing radiotherapy. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07416-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
2
|
Cox C, Castiello L, Mattei M, Santodonato L, D'agostino G, Muraro E, Martorelli D, Lapenta C, Di Napoli A, Di Landro F, Cangemi M, Pavan A, Castaldo P, Hohaus S, Donati S, Montefiore E, Berdini C, Borgioni S, Carlei D, Monque D, Ruco L, Prosperi D, Tafuri A, Spadaro F, Sestili P, Spada M, Dolcetti R, Santini S, Rozera C, Arico' E, Capone I, Belardelli F. INTRANODAL TREATMENT WITH IFNΑ-DENDRITIC CELLS AND RITUXIMAB INDUCES SYSTEMIC CLINICAL RESPONSE AND ENDOGENOUS VACCINATION AGAINST FOLLICULAR LYMPHOMA: FINAL RESULT OF A PHASE I STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.126_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C. Cox
- Haematology; AOU Sant'Andrea, Rome, Italy & King's College Foundation Trust; London United Kingdom
| | - L. Castiello
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - M. Mattei
- Radiology; AOU Sant'Andrea; Rome Italy
| | - L. Santodonato
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - G. D'agostino
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - E. Muraro
- Oncology; Centro di Riferimento Oncologico di Aviano (CRO), IRCCS; Aviano Italy
| | - D. Martorelli
- Oncology; Centro di Riferimento Oncologico di Aviano (CRO), IRCCS; Aviano Italy
| | - C. Lapenta
- Department of Oncology and Molecular Medicine; Istituto Superiore di Sanita'; Rome Italy
| | - A. Di Napoli
- Department of Clinical and Molecular Medicine; AOU Sant'Andrea; Rome Italy
| | - F. Di Landro
- Institute of Hematology; Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, IRCCS; Rome Italy
| | - M. Cangemi
- Oncology; Centro di Riferimento Oncologico di Aviano (CRO), IRCCS; Aviano Italy
| | - A. Pavan
- Department of Clinical and Molecular Medicine; AOU Sant'Andrea; Rome Italy
| | | | - S. Hohaus
- Institute of Hematology; Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, IRCCS; Rome Italy
| | - S. Donati
- Department of Oncology and Molecular Medicine; Istituto Superiore di Sanita'; Rome Italy
| | - E. Montefiore
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | | | | | - D. Carlei
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - D. Monque
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - L. Ruco
- Department of Clinical and Molecular Medicine; AOU Sant'Andrea; Rome Italy
| | - D. Prosperi
- Nuclear Medicine; AOU Sant'Andrea; Rome Italy
| | - A. Tafuri
- Department of Clinical and Molecular Medicine; AOU Sant'Andrea; Rome Italy
| | - F. Spadaro
- Department of Oncology and Molecular Medicine; Istituto Superiore di Sanita'; Rome Italy
| | - P. Sestili
- Department of Oncology and Molecular Medicine; Istituto Superiore di Sanita'; Rome Italy
| | - M. Spada
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - R. Dolcetti
- Diamantina Institute; Translational Research Institute, The University of Queensland; Brisbane Australia
| | - S. Santini
- Department of Oncology and Molecular Medicine; Istituto Superiore di Sanita'; Rome Italy
| | - C. Rozera
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - E. Arico'
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - I. Capone
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - F. Belardelli
- institute of Translational Pharmacology; CNR; Rome Italy
| |
Collapse
|
3
|
Giaj-Levra N, Trovo M, Muraro E, Fersino S, Fiorentino A, Mazzola R, Ricchetti F, Filippi A, Ricardi U, Alongi F. Report of a Pilot Study on IL-13 As Prognostic Biomarker in Patients with Early Stage Lung Cancer Treated with Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Muraro E, Vaccher E, Furlan C, Fratta E, Fae' D, Martorelli D, Polesel J, Fanetti G, Farina E, Navarria F, Comaro E, Lupato V, Giacomarra V, Sulfaro S, Barzan L, Grando G, Dolcetti R, Steffan A, Canzonieri V, Franchin G. Prognostic Significance of Immune Microenvironmental Factors in Undifferentiated Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Montico B, Lapenta C, Ravo M, Martorelli D, Muraro E, Zeng B, Comaro E, Spada M, Donati S, Santini SM, Tarallo R, Giurato G, Rizzo F, Weisz A, Belardelli F, Dolcetti R, Dal Col J. Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy. Oncoimmunology 2017; 6:e1356964. [PMID: 29147614 DOI: 10.1080/2162402x.2017.1356964] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Revised: 07/06/2017] [Accepted: 07/11/2017] [Indexed: 12/22/2022] Open
Abstract
Although promising, the clinical benefit provided by dendritic cell (DC)-based vaccines is still limited and the choice of the optimal antigen formulation is still an unresolved issue. We have developed a new DC-based vaccination protocol for aggressive and/or refractory lymphomas which combines the unique features of interferon-conditioned DC (IFN-DC) with highly immunogenic tumor cell lysates (TCL) obtained from lymphoma cells undergoing immunogenic cell death. We show that treatment of mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) cell lines with 9-cis-retinoic acid and IFNα (RA/IFNα) induces early membrane exposure of Calreticulin, HSP70 and 90 together with CD47 down-regulation and enhanced HMGB1 secretion. Consistently, RA/IFNα-treated apoptotic cells and -TCLs were more efficiently phagocytosed by DCs compared to controls. Notably, cytotoxic T cells (CTLs) generated with autologous DCs pulsed with RA/IFNα-TCLs more efficiently recognized and specifically lysed MCL or DLBCL cells or targets loaded with several HLA-A*0201 cyclin D1 or HLA-B*0801 survivin epitopes. These cultures also showed an expansion of Th1 and Th17 cells and an increased Th17/Treg ratio. Moreover, DCs loaded with RA/IFNα-TCLs showed enhanced functional maturation and activation. NOD/SCID mice reconstituted with human peripheral blood lymphocytes and vaccinated with autologous RA/IFNα-TCL loaded-IFN-DCs showed lymphoma-specific T-cell responses and a significant decrease in tumor growth with respect to mice treated with IFN-DC unpulsed or loaded with untreated TCLs. This study demonstrates the feasibility and efficacy of the use of RA/IFNα to generate a highly immunogenic TCL as a suitable tumor antigen formulation for the development of effective anticancer DC-based vaccines.
Collapse
Affiliation(s)
- B Montico
- Centro di Riferimento Oncologico, Department of Translational Research, Immunopathology and Cancer biomarkers, Aviano (PN), Italy
| | - C Lapenta
- Istituto Superiore di Sanità, Department of Hematology, Oncology and Molecular Medicine, Rome, Italy
| | - M Ravo
- Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi (SA), Italy
| | - D Martorelli
- Centro di Riferimento Oncologico, Department of Translational Research, Immunopathology and Cancer biomarkers, Aviano (PN), Italy
| | - E Muraro
- Centro di Riferimento Oncologico, Department of Translational Research, Immunopathology and Cancer biomarkers, Aviano (PN), Italy
| | - B Zeng
- The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia
| | - E Comaro
- Centro di Riferimento Oncologico, Department of Translational Research, Immunopathology and Cancer biomarkers, Aviano (PN), Italy
| | - M Spada
- Istituto Superiore di Sanità, Department of Hematology, Oncology and Molecular Medicine, Rome, Italy
| | - S Donati
- Istituto Superiore di Sanità, Department of Hematology, Oncology and Molecular Medicine, Rome, Italy
| | - S M Santini
- Istituto Superiore di Sanità, Department of Hematology, Oncology and Molecular Medicine, Rome, Italy
| | - R Tarallo
- Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi (SA), Italy
| | - G Giurato
- Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi (SA), Italy.,Genomix4Life srl, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi (SA), Italy
| | - F Rizzo
- Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi (SA), Italy
| | - A Weisz
- Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi (SA), Italy
| | - F Belardelli
- Istituto Superiore di Sanità, Department of Hematology, Oncology and Molecular Medicine, Rome, Italy
| | - R Dolcetti
- Centro di Riferimento Oncologico, Department of Translational Research, Immunopathology and Cancer biomarkers, Aviano (PN), Italy.,The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia
| | - J Dal Col
- Centro di Riferimento Oncologico, Department of Translational Research, Immunopathology and Cancer biomarkers, Aviano (PN), Italy.,Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi (SA), Italy
| |
Collapse
|
6
|
Muraro E, Comaro E, Talamini R, Turchet E, Miolo G, Scalone S, Militello L, Lombardi D, Spazzapan S, Perin T, Massarut S, Crivellari D, Dolcetti R, Martorelli D. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. J Transl Med 2015; 13:204. [PMID: 26116238 PMCID: PMC4483222 DOI: 10.1186/s12967-015-0567-0] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2015] [Accepted: 06/09/2015] [Indexed: 12/22/2022] Open
Abstract
Background Locally advanced HER2-overexpressing breast cancer (BC) patients achieve a high rate of pathological complete responses (pCR) after neoadjuvant chemotherapy (NC). The apparently unaltered immune proficiency of these patients together with the immune-modulating activities of NC drugs suggest a potential contribution of host immunity in mediating clinical responses. We thus performed an extensive immunomonitoring in locally advanced BC patients undergoing NC to identify immunological correlates of pCR induction. Methods The immune profile of 40 HER2-positive and 38 HER2-negative BC patients was characterized at diagnosis and throughout NC (Paclitaxel and Trastuzumab, or Docetaxel and Epirubicin, respectively). The percentages of circulating immune cell subsets including T and B lymphocytes, Natural Killer (NK) cells, regulatory T cells, T helper 17 lymphocytes, were quantified by multiparametric flow cytometry. NK cells functional activity was evaluated through the analysis of NF-kB nuclear translocation by Multispectral flow cytometry, and with the in vitro monitoring of Trastuzumab-mediated antibody-dependent cell cytotoxicity (ADCC). CD8+ T cell responses against six different tumor-associated antigens (TAA) were characterized by IFN-γ ELISPOT and IFN-γ/IL-2 DualSpot assays. Results After NC, HER2-positive patients showed a significant increase in the number of NK cells and regulatory T cells irrespective of the pathological response, whereas patients undergoing a pCR disclosed higher percentages of T helper 17 cells. Notably, a significant increase in the number of activated NK cells was observed only in HER2-positive patients achieving a pCR. Characterization of anti-tumor T cell responses highlighted sustained levels of CD8+ T cells specific for survivin and mammaglobin-A throughout NC in patients undergoing a pCR in both arms. Moreover, HER2-positive patients achieving a pCR were characterized by a multi-epitopic and polyfunctional anti-tumor T cell response, markedly reduced in case of partial response. Conclusions These results indicate that maintenance of functional T cell responses against selected antigens and improvement of NK cell proficiency during NC are probably critical requirements for pCR induction, especially in HER2-positive BC patients. Trail registration: Trial registration number: NCT02307227, registered on ClinicalTrials.gov (http://www.clinicaltrials.gov, November 26, 2014). Electronic supplementary material The online version of this article (doi:10.1186/s12967-015-0567-0) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- E Muraro
- Cancer Bio-Immunotherapy Unit, Department of Translational Research, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - E Comaro
- Cancer Bio-Immunotherapy Unit, Department of Translational Research, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - R Talamini
- Unit of Epidemiology and Biostatistics, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - E Turchet
- Scientific Direction, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - G Miolo
- Department of Medical Oncology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - S Scalone
- Department of Medical Oncology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - L Militello
- Department of Medical Oncology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - D Lombardi
- Department of Medical Oncology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - S Spazzapan
- Department of Medical Oncology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - T Perin
- Department of Pathology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - S Massarut
- Division of Breast Surgical Oncology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - D Crivellari
- Department of Medical Oncology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - Riccardo Dolcetti
- Cancer Bio-Immunotherapy Unit, Department of Translational Research, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - D Martorelli
- Cancer Bio-Immunotherapy Unit, Department of Translational Research, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| |
Collapse
|
7
|
Alessi M, Fabris A, Zambon A, Cremasco D, Muraro E, Dosa L, Anglani F, Del Prete D. Pregnancy in Alport syndrome: a report of two differently-evolving cases. J OBSTET GYNAECOL 2014; 34:98-100. [PMID: 24359068 DOI: 10.3109/01443615.2013.834299] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
8
|
Fae' D, Martorelli D, Muraro E, Mastorci K, Vaccher E, Barzan L, Franchin G, Comaro E, Carbone A, Dolcetti R. 1085 Generation of EBV-specific CTL Lines Enriched in BARF1 Specificities for Improved Adoptive Immunotherapy of Nasopharyngeal Carcinoma. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71691-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
9
|
Muraro E, Martorelli D, Bomben R, Fabris M, DeRe V, Gattei V, Anichini A, Dolcetti R. 1086 IGHV1-69 as a Promising Candidate for the Development of a Shared Immunotherapy to B-cell Lymphomas. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71692-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Inazu T, Kawahara T, Endou H, Anzai N, Sebesta I, Stiburkova B, Ichida K, Hosoyamada M, Testa A, Testa A, Leonardis D, Catalano F, Pisano A, Mafrica A, Spoto B, Sanguedolce MC, Parlongo RM, Tripepi G, Postorino M, Enia G, Zoccali C, Mallamaci F, Working Group* M, Luque de Pablos A, Garcia-Nieto V, Lopez-Menchero JC, Ramos-Trujillo E, Gonzalez-Acosta H, Claverie-Martin F, Arsali M, Demosthenous P, Papazachariou L, Athanasiou Y, Voskarides K, Deltas C, Pierides A, Lee S, Jeong KH, Ihm C, Lee TW, Lee SH, Moon JY, Wi JG, Lee HJ, Kim EY, Rogacev K, Friedrich A, Hummel B, Berg J, Zawada A, Fliser D, Geisel J, Heine GH, Brabcova I, Brabcova I, Dusilova-Sulkova S, Dusilova-Sulkova S, Krejcik Z, Stranecky V, Lipar K, Marada T, Stepankova J, Viklicky O, Buraczynska M, Zukowski P, Zaluska W, Kuczmaszewska A, Ksiazek A, Gaggl M, Weidner S, Hofer M, Kleinert J, Fauler G, Wallner M, Kotanko P, Sunder-Plassmann G, Paschke E, Heguilen R, Heguilen R, Albarracin L, Politei J, Liste AA, Bernasconi A, Kusano E, Russo R, Pisani A, Messalli G, Imbriaco M, Prikhodina L, Ryzhkova O, Polyakov V, Lipkowska K, Ostalska-Nowicka D, Smiech M, Jaroniec M, Zaorska K, Szaflarski W, Nowicki M, Zachwieja J, Spoto B, Spoto B, Testa A, Sanguedolce MC, D'arrigo G, Parlongo RM, Pisano A, Tripepi G, Zoccali C, Mallamaci F, Moskowitz J, Piret S, Tashman A, Velez E, Lhotta K, Thakker R, Kotanko P, Cox J, Kingswood J, Mbundi J, Attard G, Patel U, Saggar A, Elmslie F, Doyle T, Jansen A, Jozwiak S, Belousova E, Frost M, Kuperman R, Bebin M, Korf B, Flamini R, Kohrman M, Sparagana S, Wu J, Ford J, Shah G, Franz D, Zonnenberg B, Cheung W, Urva S, Wang J, Frost M, Kingswood C, Budde K, Kofman T, Narjoz C, Raimbourg Q, Roland M, Loriot MA, Karras A, Hill GS, Jacquot C, Nochy D, Thervet E, Jagodzinski P, Mostowska M, Oko A, Nicolaou N, Kevelam S, Lilien M, Oosterveld M, Goldschmeding R, Van Eerde A, Pfundt R, Sonnenberg A, Ter Hal P, Knoers N, Renkema K, Storm T, Nielsen R, Christensen E, Frykholm C, Tranebjaerg L, Birn H, Verroust P, Neveus T, Sundelin B, Hertz JM, Holmstrom G, Ericson K, Fabris A, Cremasco D, Zambon A, Muraro E, Alessi M, D'angelo A, Anglani F, Del Prete D, Alkmim Teixeira A, Quinto BM, Jose Rodrigues C, Beltrame Ribeiro A, Batista M, Kerti A, Kerti A, Csohany R, Szabo A, Arkossy O, Sallai P, Moriniere V, Vega-Warner V, Lakatos O, Szabo T, Reusz G, Tory K, Addis M, Anglani F, Tosetto E, Meloni C, Ceol M, Cristofaro R, Melis MA, Vercelloni P, D'angelo A, Marra G, Kaniuka S, Nagel M, Wolyniec W, Obolonczyk L, Swiatkowska-Stodulska R, Sworczak K, Rutkowski B, Chen C, Jiang L, Chen L, Fang L, Mozes M. M, Boosi M, Rosivall L, Kokeny G, Diana R, Gross O, Johanna T, Rainer G, Ayse C, Henrik H, Gerhard-Anton M, Nabil M, Intissar E, Belge H, Belge H, Bloch J, Dahan K, Pirson Y, Vanhille P, Demoulin N. Genetic diseases. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs232] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Dolcetti R, Crivellari D, Muraro E, Martorelli D, Miolo G, Lombardi D, Massarut S, Perin T, Talamini R, Turchet E, Comaro E, Carbone A, Veronesi A. Immunologic profiling and clinical outcome in HER2+ breast cancer patients treated in a neoadjuvant phase II study: A step forward to understand trastuzumab activity. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|